J.P. Morgan analyst Cory Kasimov maintained a Sell rating on Jounce Therapeutics Inc (JNCE) on May 8. The company’s shares closed on Friday at $5.90.
According to TipRanks.com, Kasimov is a 2-star analyst with an average return of 0.5% and a 41.2% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Jounce Therapeutics Inc with a $13 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.45 and a one-year low of $2.66. Currently, Jounce Therapeutics Inc has an average volume of 207.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting.
